Upstream Bio, Inc. (UPB)
$3.42-3.66%Close
SELLCRISIS · day 33
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $186M
- Beta
- 1.39
- P/E (TTM)
- -1.18
- Short % float
- 22.48%
- Days to cover
- 7.7
- SI change
- +0.5%
- 1W
- -25.81%
- 1M
- -37.59%
- vs SPY 1W
- -25.67%
- vs SPY 1M
- -40.10%
Industry peers
FMP comparable companies · ranked by market cap
- SYRESELLSpyre Therapeutics, Inc.$7.4BCRISISQ 9$85.69-2.26%
- TERNTerns Pharmaceuticals, Inc.$6.1B$52.95
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 2$17.88-1.73%
- AMLXSELLAmylyx Pharmaceuticals, Inc.$3.1BCRISISQ 7$28.14+0.67%
- PHVSSELLPharvaris N.V.$2.2BCRISISQ 15$31.10+0.00%
- NVAXBUYNovavax, Inc.$2.1BBULLQ 10$12.75-1.40%
- NTLASELLIntellia Therapeutics, Inc.$1.8BRECOVERYQ 3$13.07-4.03%
- ZBIOSELLZenas BioPharma, Inc.$1.7BCRISISQ 12$27.26-1.19%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 15$16.99-3.01%
- WVESELLWave Life Sciences Ltd.$682MCRISISQ 7$3.46-1.59%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 19
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-29.0%
REV YoY-
ROE-48.4%
EPS YoY-
ROA-55.7%
GROSS98
OP-5383
NET-4956
[VALUATION]
P/E TTM-1.18
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.69
P/FCF-
EV/EBITDA-0.69
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.35
ALTMAN Z-
CURR RATIO27.99
ND/EBITDA-
BETA1.39
Company news
FAQ
- What is LOPJLB’s current signal on UPB?
- LOPJLB’s latest quantitative signal on Upstream Bio, Inc. (UPB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is UPB in?
- Upstream Bio, Inc. (UPB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Upstream Bio, Inc. (UPB) do?
- Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively develo…